Literature DB >> 24474248

Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.

Nicholas S Downing1, Joseph S Ross2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24474248     DOI: 10.1001/jama.2014.148

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Marketing of personalized cancer care on the web: an analysis of Internet websites.

Authors:  Stacy W Gray; Angel Cronin; Elizabeth Bair; Neal Lindeman; Vish Viswanath; Katherine A Janeway
Journal:  J Natl Cancer Inst       Date:  2015-03-05       Impact factor: 13.506

Review 2.  Use of contemporary genetics in cardiovascular diagnosis.

Authors:  Alfred L George
Journal:  Circulation       Date:  2014-11-25       Impact factor: 29.690

3.  The audacity of interpretation: Protecting patients or piling on?

Authors:  Misha Angrist
Journal:  Appl Transl Genom       Date:  2014-09-01

Review 4.  Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing.

Authors:  Seon-Hee Yim; Yeun-Jun Chung
Journal:  Genomics Inform       Date:  2014-12-31

5.  Gatekeepers or intermediaries? The role of clinicians in commercial genomic testing.

Authors:  Michelle L McGowan; Jennifer R Fishman; Richard A Settersten; Marcie A Lambrix; Eric T Juengst
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

6.  Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.

Authors:  Aihua Li; David Meyre
Journal:  Curr Psychiatry Rev       Date:  2014-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.